Drugs / MEN1703
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06534437 | Dec 2024 → Dec 2026 expected | aggressive B-cell non-Hodgkin lymphoma | Ryvu Therapeutics SA | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEN1703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06534437 ↗ |
| Action | Inhibit | “is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3)” NCT06534437 ↗ |
| Route | Oral | “will be given MEN1703 orally at a dose of 150 mg daily” NCT06534437 ↗ |